• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24395 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     WorkSafeBC Restless legs syndrome (RLS) and post-traumatic stress disorder (PTSD): 2024 update
2024     NIHR Health Technology Assessment programme Interventions for primary prevention of cardiovascular disease: umbrella review of systematic reviews
2024     NIHR Health Services and Delivery Research programme Digital First Primary Care for those with multiple long-term conditions: a rapid review of the views of stakeholders
2024     WorkSafeBC Best practices for preventing psychological injury to front-line community support workers
2024     NIHR Health Technology Assessment programme Bezafibrate as treatment in males for Barth syndrome: CARDIOMAN, a double-blind, placebo-controlled crossover RCT
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Checklist: screening for cancers, chronic diseases and STBBIs]
2024     NIHR Health Technology Assessment programme Accuracy of glomerular filtration rate estimation using creatinine and cystatin C for identifying and monitoring moderate chronic kidney disease: the eGFR-C study
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: care management for youth under 18 with attention deficit hyperactivity disorder (ADHD)]
2024     WorkSafeBC COVID-19 and multiple sclerosis relapse
2024     NIHR Health Services and Delivery Research programme Causes and solutions to workplace psychological ill-health for nurses, midwives and paramedics: the Care Under Pressure 2 realist review
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: reducing the carbon footprint of anesthetic agents inhaled in the operating room during general anesthesia - strategies and challenges to consider]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection acc. to the Law for More Safety in the Supply of Medicines (GSAV): talquetamab (multiple myeloma)]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: environmental impacts in health and social services - what role should health technology assessment agencies play?]
2024     WorkSafeBC Low-dose naltrexone as treatment for post-Covid conditions: first update
2024     Penn Medicine Center for Evidence-based Practice (CEP) Renal denervation for treatment of resistant hypertension
2024     National Institute for Health and Care Excellence (NICE) Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome. NICE highly specialised technologies guidance 31
2024     WorkSafeBC Risk factors associated with the development or acceleration of degenerative disc disease for helicopter pilots - 2024 update
2024     NIHR Health Technology Assessment programme Establishing a research partnership to investigate functional loss and rehabilitation towards the end of life
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daridorexant (insomnia) – Benefit assessment according to §35a Social Code Book V]
2024     National Institute for Health and Care Excellence (NICE) Sebelipase alfa for treating Wolman disease. NICE highly specialised technologies guidance 30
2024     Health Sciences Institute in Aragon (IACS) [Methods for the quantification of direct-acting oral anticoagulants in plasma]
2024     WorkSafeBC Compartment syndrome and collagen structure
2024     Penn Medicine Center for Evidence-based Practice (CEP) Patient hand hygiene before meals for infection control
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enalapril (heart failure, children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2024     NIHR Health Services and Delivery Research programme Evaluation of different models of general practitioners working in or alongside emergency departments: a mixed-methods realist evaluation
2024     Canary Health Service [Effectiveness, safety, and cost-effectiveness of out-of-hospital cardiac rehabilitation for ischemic heart disease or heart failure]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zilucoplan (generalized myasthenia gravis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: delirium in elderly persons in emergency departments - prevention, assessment and management]
2024     Canary Health Service [Effectiveness, safety and cost-effectiveness of automated systems for detecting adverse drug reactions]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nirsevimab (prevention of RSV disease) – Benefit assessment according to §35a Social Code Book V]
2024     NIHR Health Technology Assessment programme Advice only versus advice and a physiotherapy programme for acute traumatic anterior shoulder dislocation: the ARTISAN RCT
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating osteodensitometry following the assessment of fracture risk with the FRAX tool]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decitabine/cedazuridine (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V]
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Alemtuzumab, cladribine, fingolimod, and natalizumab as first-line treatments in adult patients with highly active relapsing multiple sclerosis
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: intravesical treatment for bladder cancer]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idecabtagene vicleucel (multiple myeloma, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V]
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Renal denervation
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: major depressive disorder during pregnancy]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Efgartigimod alfa (generalized myasthenia gravis) – Benefit assessment according to §35a Social Code Book V]
2024     Ontario Health Intrathecal drug delivery systems for cancer pain
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: judicious use of medical biology tests in the diagnosis and treatment of Helicobacter pylori infection]
2024     Health Technology Wales (HTW) Artificial Intelligence (AI)-assisted endoscopy in the detection of gastrointestinal cancer and pre-cancerous lesions
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Gadopiclenol (contrast-enhanced magnetic resonance imaging) – Benefit assessment according to §35a Social Code Book V]
2024     Belgian Health Care Knowledge Centre (KCE) The use of endothelial cell count in the preoperative evaluation of cataract surgery
2024     NIHR Health Services and Delivery Research programme Linkage of routinely collected NHS data to evaluate liaison mental health services: challenges and lessons learned
2024     Health Technology Wales (HTW) Artificial intelligence assisted tools for prostate cancer diagnosis using whole slide biopsy images
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for etranacogene dezaparvovec (haemophilia B): Review of the study protocol (Version 2.0) and statistical analysis plan (Version 2.0) – Third addendum to Commission A22-83]
2024     Belgian Health Care Knowledge Centre (KCE) Lung cancer screening in a high-risk population
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: genomic medicine in healthcare systems - challenges and opportunities]
2024     Health Technology Wales (HTW) FloSeal in the treatment of epistaxis
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abaloparatide (osteoporosis, postmenopausal women) – Benefit assessment according to §35a Social Code Book V]
2024     Belgian Health Care Knowledge Centre (KCE) Diagnostic Immunohistochemistry and electron microscopy testing in Belgium
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: overview of polypharmacy and use of potentially inappropriate medications among people aged 65 and over in Quebec]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etrasimod (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V]
2024     NIHR Health Technology Assessment programme Point-of-care tests for urinary tract infections to reduce antimicrobial resistance: a systematic review and conceptual economic model
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Rigid-platform (TEM/ TEO) or flexible-platform (TAMIS) endoscopic transanal surgery for the treatment of rectal lesions]
2024     NIHR Health Technology Assessment programme Development and evaluation of machine-learning methods in whole-body magnetic resonance imaging with diffusion weighted imaging for staging of patients with cancer: the MALIBO diagnostic test accuracy study
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Letermovir (prophylaxis of CMV reactivation and disease after stem cell transplantation) - Addendum to Project A23-139]
2024     NIHR Health Technology Assessment programme Collagenase injection versus limited fasciectomy surgery to treat Dupuytren’s contracture in adult patients in the UK: DISC, a non-inferiority RCT and economic evaluation
2024     National Institute for Health and Care Excellence (NICE) Kurin Lock for blood culture collection. NICE medical technologies guidance 77
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for valoctocogene roxaparvovec: Review of the study protocol (Version 3.0) and statistical analysis plan (Version 3.0) – Fourth addendum to Project A22-20]
2024     NIHR Health and Social Care Delivery Program Early mental health intervention and supported self-care for LGBTQ+ young people in the UK: a mixed-methods study
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Methodology report: glossary of terms used in pharmacoeconomics]
2024     National Institute for Health and Care Excellence (NICE) GaitSmart rehabilitation exercise programme for gait and mobility issues. NICE medical technologies guidance 78
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (gastric and gastro-oesophageal junction adenocarcinoma, HER2-positive) – Addendum to Project A24-01]
2024     NIHR Health Technology Assessment programme Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant data sets
2024     NIHR Health Technology Assessment programme Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT
2024     Scottish Health Technologies Group (SHTG) Living Donor Transplantation - SHTG Assessment
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: linezolid plasma dosing]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Addendum to Project A23-143]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polatuzumab vedotin (combination with rituximab, cyclophosphamide, doxorubicin and prednisone; previously untreated DLBCL) – Addendum to Project A23-141]
2024     NIHR Health Services and Delivery Research programme Service design for children and young people with common mental health problems: literature review, service mapping and collective case study
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for talquetamab (multiple myeloma) - First addendum to Project A23-100]
2024     NIHR Health Technology Assessment programme Clinical and cost‐effectiveness of pessary self‐management versus clinic-based care for pelvic organ prolapse in women: the TOPSY RCT with process evaluation
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Measurement and monitoring of pulmonary arterial pressure by means of implanted sensor for treatment optimization in heart failure stage NYHA III - Addendum to Project D23-02]
2024     NIHR Health Technology Assessment programme Doppler ultrasound surveillance of recently formed haemodialysis arteriovenous fistula: the SONAR observational cohort study
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcutaneous vagus nerve stimulation in pharmacoresistant epilepsy]
2024     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Epcoritamab (diffuse large B-cell lymphoma, after ≥ 2 prior therapies)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcutaneous vagus nerve stimulation in pharmacoresistant epilepsy - Addendum to Commission E16-03]
2024     Swiss Federal Office of Public Health (FOPH) Tumor treating fields (TTFields) therapy for patients with glioblastoma multiforme
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: breast cancer screening with breast tomosynthesis]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcutaneous vagus nerve stimulation in pharmacoresistant epilepsy – Second addendum to Commission E16-03]
2024     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Safety, efficacy, effectiveness, and efficiency of systematic neonatal screening for the detection of congenital cytomegalovirus]
2024     Swiss Federal Office of Public Health (FOPH) CAR-T-cell therapies
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rozanolixizumab (myasthenia gravis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Omaveloxolone (Friedreich’s ataxia) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Swiss Federal Office of Public Health (FOPH) Treatment duration of trastuzumab in early HER2-positive breast cancer
2024     NIHR Health Services and Delivery Research programme Factors influencing effective data sharing between health care and social care regarding the care of older people: a qualitative evidence synthesis
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polatuzumab vedotin (relapsed or refractory DLBCL) – Addendum to Project A23-140]
2024     Health Sciences Institute in Aragon (IACS) Programme for the use of real world data in health technology assessment. Potential uses for real world data in the Spanish HTA Network
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elranatamab (multiples Myelom) - Addendum zum Projekt A24-12]
2024     NIHR Health Services and Delivery Research programme Evaluating the real-world implementation of the Family Nurse Partnership in England: a data linkage study
2024     Swiss Federal Office of Public Health (FOPH) Intra-articular glucocorticoid injections for osteoarthritis of the hip or knee
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: continuous positive airway pressure devices for the treatment of obstructive sleep apnea]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: initial evaluation of lung cancer patients for whom surgery is the first treatment – portrait of the situation in Québec from 2016 to 2019]
2024     NIHR Health Services and Delivery Research programme A service-user digital intervention to collect real-time safety information on acute, adult mental health wards: the WardSonar mixed-methods study
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of STAT1 phosphorylation status by flow cytometry]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Metformin: Evidence report for the S3 guideline on gestational diabetes mellitus (GDM) – diagnosis, treatment and follow-up care]
2024     Canary Health Service [Cost-effectiveness of universal vaccination against pneumococcal disease with the new conjugate vaccines against 15 and 20 serotypes]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lifestyle interventions with the aim of lowering blood sugar levels: Evidence report for the S3 guideline on gestational diabetes mellitus (GDM) – diagnosis, treatment and follow-up care]